• EU regulators extended the indication for Sanofi’s MenQuadfi vaccine to include infants from six weeks of age.
• The label expansion broadens EU market access beyond the prior authorization for people aged 12 months and older.
• The European Commission decision follows a positive CHMP opinion dated June 25, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040100OMX_____CNEWS_EN_GNW1001255871_en) on August 04, 2026, and is solely responsible for the information contained therein.